ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2® for the Treatment of Celiac Disease | Business Wire
ImmusanT Announces Completion of Phase 1b Clinical Trial for Celiac Disease Treatment - Drug Discovery and Development
A Journey Through the Nexvax2 "Celiac Disease Vaccine" Clinical Trial - Celiac.com
World's first celiac vaccine gains FDA fast-track designation during Phase 2 trial
ImmusanT starts trials of celiac disease vaccine, Nexvax2
Startup Pioneers Celiac Disease Remedy
Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease | Request PDF
ImmusanT's Nexvax2 demonstrates positive outcome in Phase Ib trial to treat coeliac disease - Clinical Trials Arena
Celiac Vaccine Trial Participant Shares Experience With Nexvax2 - Gluten-Free Living
Nexvax2 Setback Only One Aspect of Ongoing Scientific Discovery | BeyondCeliac.org
ImmusanT goes on hiring spree ahead of phase 2 celiac vaccine trial | Fierce Biotech
Discontinuation of the Nexvax2 Phase 2 trial - Coeliac New Zealand
Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies - ScienceDirect
Celiac disease vaccine clinical trial canceled — here's a local expert's response | PhillyVoice
Celiac Disease Vaccine Candidate Nexvax2 Shows Promise — Precision Vaccinations
Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease
Randomised clinical trial: a placebo‐controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease - Truitt - 2019 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Study overview. The pilot study included two participants prior to... | Download Scientific Diagram
Celiac Disease Cure? ImmusanT Tests Nexvax2 in Clinical Trials - Xtalks
A Participant's Perspective on the Failure of the Nexvax2 "Celiac Disease Vaccine" Clinical Trial - Celiac.com
Epitope-specific immunotherapy: a vaccine for coeliac disease? - The Lancet Gastroenterology & Hepatology
Beyond Celiac on Twitter: "RESEARCH NEWS: Nexvax2 vaccine protects against high doses of gluten, study shows. Read more about the Nexvax2 vaccine here: https://t.co/A8eqESeLVJ #celiac #celiacresearch #Nexvax2 @ImmusanT" / Twitter
Nexvax2 Therapeutic Vaccine | Celiac Disease Foundation
Frontiers | Vaccine Immunotherapy for Celiac Disease | Medicine
